Achieve Life Sciences Secures $354M Financing as It Preps Cytisinicline Resubmission
Event summary
- Closed $354M private placement ($180M upfront, $174M in milestone-based warrants)
- Received FDA Complete Response Letter (CRL) citing manufacturing and labeling issues, not efficacy/safety
- Transitioned finished drug product manufacturing to U.S.-based Adare Pharma Solutions
- Strengthened leadership with new CEO, commercial team, and six Board appointments
The big picture
Achieve Life Sciences is positioning itself for a potential 2027 launch of cytisinicline, a nicotine dependence treatment with Breakthrough Therapy designation. The $354M financing provides runway as the company navigates FDA requirements and prepares for commercialization in a market where smoking remains the leading cause of preventable death. The leadership overhaul suggests a focus on execution as Achieve aims to capitalize on its manufacturing transition and regulatory path forward.
What we're watching
- Regulatory Timeline
- Whether Achieve can secure FDA approval in the first half of 2027 following NDA resubmission.
- Commercial Readiness
- The pace at which Achieve builds its commercial team and infrastructure for cytisinicline launch.
- Manufacturing Execution
- How smoothly the transition to Adare Pharma Solutions proceeds and whether it avoids further regulatory hurdles.
Related topics